Weidong Jia

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Zhenggang Ren, Jianming Xu, Yuxian Bai et al. · The Lancet Oncology · 2021 · 1K citations

Hepatology, Bevacizumab Biosimilar, Medicine +8

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)

Jian Zhou, Hui‐Chuan Sun, Zheng Wang et al. · Liver Cancer · 2020 · 813 citations · Full text

Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Shukui Qin, Stephen L. Chan, Shanzhi Gu et al. · The Lancet · 2023 · 590 citations

First-line Therapy, Hepatology, International Phase 3 +8

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Jian Zhou, Hui‐Chuan Sun, Zheng Wang et al. · Liver Cancer · 2023 · 389 citations · Full text

ENO1 suppresses cancer cell ferroptosis by degrading the mRNA of iron regulatory protein 1

Tong Zhang, Linchong Sun, Yijie Hao et al. · Nature Cancer · 2021 · 192 citations

Reductive Stress, Natural Sciences, Metalloprotein +9